Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3470
Full Text
Open PDFAbstract
Available in full text
Date
March 19, 2019
Authors
Publisher
American Association for Cancer Research (AACR)